- Global Pharma News & Resources

Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022

 Warsaw, Poland – 5 December 2022 – Molecure S.A. (“Molecure”: WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces agenda topics and participating key opinion leaders for its virtual R&D Day.

The webcast event will be hosted by Molecure on the 7th December 2022 at 13.30 - 16.30 CET / 12.30 – 15.30 BST/ 7.30 – 10.30 ET.

The meeting is available here:

The presentations by Key Opinion Leaders and Molecure management will showcase the scientific insights and clear clinical needs that underpin Molecure’s pipeline programs.

Agenda topics:


  • Molecure’s Vision, Strategy and Pipeline
  • OATD-01, Molecure’s first in class chitinase inhibitor:
  • Clinical evaluation in sarcoidosis and potential patient impact (Prof. Krenke)
  • Landscape and therapy opportunity in sarcoidosis
  • Clinical development plan
  • Other opportunities in interstitial lung disease
  • OATD-02, Molecure’s novel dual arginase inhibitor:
  • Pre-clinical activity in a broad range of cancers
  • State of oncology in Poland (Prof. Szczylik)
  • Clinical development plan

15.30-15.40 Break


  • Early-stage pipeline
  • Deubiquitinating enzymes (DUBs) program including USP7 in oncology
  • YKL40 in oncology
  • University of Michigan collaboration in fibrosis
  • mRNA platform

Key Opinion Leader Presenters:

  • Prof. Rafal Krenke, Pulmonologist, Head of Department of Internal Medicine, Pulmonary Diseases & Allergy, Medical University of Warsaw
  • Prof. Cezary Szczylik, Oncologist, Head of the Department of Clinical Oncology and Chemotherapy Europejskie Centrum Zdrowia (European Health Center) Otwock

Molecure S.A. Presenters:

  • Dr Marcin Szumowski     - CEO, President of the Board
  • Dr Zbigniew Zasłona       - VP Research Biology, Member of the Board
  • Dr Samson Fung              - Chief Medical Officer
  • Dr Nicolas Beuzen           - Director of Business Development and Licensing

Editor Details

Related Links

Last Updated: 06-Dec-2022